Navigation Links
GeoVax Labs, Inc. Announces First Quarter Financial Results
Date:4/27/2011

60;Preclinical work enabling evaluation of the GeoVax DNA and MVA vaccines was funded and supported by the National Institute of Allergy and Infectious Disease (NIAID), which provided additional support to the GeoVax vaccine development program with a $19 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant awarded in late 2007.

For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether:  HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

FINANCIAL TABLES FOLLOWGEOVAX LABS, INC.Condensed Consolidated
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
2. GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony
3. GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
4. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
5. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
6. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
7. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
8. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
9. GeoVax Labs Requests pre-IND Meeting With FDA
10. GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
11. GeoVax Labs, Inc. Provides Clinical Studies Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of the "Gene Therapy Market, 2015 - ... The "Gene Therapy Market, 2015-2025" report provides an extensive ... lot of research has been carried out in this ... five approved therapies (four available in Asian markets; one ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Most school districts still are not teaching skills needed for ... are behind in understanding that we are way beyond the ... teaching the classical three Rs. I am not talking about ... and routine. All of these add up to regimentation, which ...
... Wis. - Cray Inc. , the Seattle-based ... here, has been awarded a $250 million agreement from ... to develop what the company calls a revolutionary ... Chippewa Falls operation remains unclear. , ,The agreement, which ...
... Wisconsin has a chance to attract a major federal laboratory. It ... Health Center was established in Madison, and nearly 100 years ... University of Michigan as the site for the ... the world's knowledge of wildlife diseases and forests - as well ...
Cached Biology Technology:Rote education fails the Information Age 2Rote education fails the Information Age 3Rote education fails the Information Age 4Cray signs $250M deal to develop supercomputer 2National Bio and Agro Defense fits Wisconsin 2National Bio and Agro Defense fits Wisconsin 3National Bio and Agro Defense fits Wisconsin 4
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... likely to happen - you being in a car wreck or ... are greater killers win a free trip to the beach. It's ... of being in a wreck are far greater than being a ... sciences who has studied sharks for years. , Worldwide, about one ...
... Providing safer shellfish is the goal of Agricultural Research ... which pathogenic bacteria enter shellfish. , In the United ... of concern: V. vulnificus and V. parahaemolyticus. These bacteria ... water temperatures are warm, and can lead to serious ...
... sleep-deprived months with your newborn were tough, pity the ... the June 30 edition of the peer-reviewed journal Nature, ... dolphins and killer whales that is unique from other ... a day during their first month. , The mother ...
Cached Biology News:Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research 2Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development 2